Fertomid: Clinically Proven Ovulation Induction Therapy
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.52 | $45.58 (0%) | 🛒 Add to cart |
| 60 | $1.29 | $91.16 $77.40 (15%) | 🛒 Add to cart |
| 90 | $1.20 | $136.74 $108.36 (21%) | 🛒 Add to cart |
| 120 | $1.17 | $182.32 $140.18 (23%) | 🛒 Add to cart |
| 180 | $1.13 | $273.48 $203.82 (25%) | 🛒 Add to cart |
| 270 | $1.11 | $410.22 $299.28 (27%) | 🛒 Add to cart |
| 360 | $1.09
Best per pill | $546.96 $393.88 (28%) | 🛒 Add to cart |
Fertomid (clomiphene citrate) represents a first-line therapeutic option for ovulation induction in anovulatory women seeking fertility treatment. As a selective estrogen receptor modulator (SERM), it works by blocking estrogen receptors in the hypothalamus, thereby increasing gonadotropin-releasing hormone (GnRH) secretion and subsequent follicle-stimulating hormone (FSH) production. This medication has been extensively studied in clinical settings and remains a cornerstone treatment for ovulatory dysfunction. Proper patient selection and monitoring are essential for optimizing treatment outcomes while minimizing potential risks associated with therapy.
Features
- Contains 50mg clomiphene citrate per tablet
- Selective estrogen receptor modulator (SERM) class
- Oral administration with high bioavailability
- Standardized manufacturing under GMP guidelines
- White, round, biconvex film-coated tablets
- Typically supplied in blister packs of 10 tablets
Benefits
- Effectively induces ovulation in approximately 80% of appropriately selected anovulatory patients
- Restores regular menstrual cycles in women with ovulatory dysfunction
- Non-invasive oral administration compared to injectable alternatives
- Cost-effective first-line treatment option for infertility
- Well-established safety profile with decades of clinical use
- Enables timed intercourse or assisted reproductive techniques
Common use
Fertomid is primarily indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. The medication is particularly effective in patients with polycystic ovary syndrome (PCOS) and other conditions characterized by anovulation. Treatment should be initiated only after thorough evaluation has confirmed the absence of other fertility factors requiring alternative management. Physicians typically recommend concomitant monitoring through ultrasound follicular tracking and/or serum progesterone measurements to confirm ovulation and optimize timing.
Dosage and direction
The recommended initial dosage is 50mg (one tablet) daily for five days, beginning on the third, fourth, or fifth day of menstrual bleeding. Treatment may be initiated at any time in patients with amenorrhea. The dosage may be increased to 100mg daily for five days in subsequent cycles if ovulation does not occur at the lower dose. Maximum recommended dosage is 150mg daily for five days. Treatment beyond three to six cycles is generally not recommended due to decreasing efficacy and potential endometrial effects. Administration should occur at approximately the same time each day, with or without food.
Precautions
Patients should undergo complete gynecologic and endocrine evaluation before initiation of therapy. Visual symptoms should be thoroughly evaluated and may necessitate discontinuation. Multiple pregnancy occurs in approximately 8% of pregnancies, with most being twins. Ovarian hyperstimulation syndrome (OHSS) may occur, particularly in patients with polycystic ovarian disease. Long-term use (超过 12 cycles) may increase the risk of borderline ovarian tumors. Endometrial thickness should be monitored in patients receiving multiple treatment cycles.
Contraindications
Fertomid is contraindicated in patients with liver disease or abnormal liver function tests, pre-existing ovarian cysts (not associated with polycystic ovarian syndrome), abnormal uterine bleeding of undetermined origin, thyroid or adrenal dysfunction, organic intracranial lesions such as pituitary tumors, and hypersensitivity to clomiphene citrate or any component of the formulation. The medication must not be administered during pregnancy due to potential fetal harm.
Possible side effects
Common adverse reactions include vasomotor flushes (10%), abdominal discomfort (7%), ovarian enlargement (5%), breast tenderness (2%), and visual disturbances (1.5%). Less frequently reported effects include nausea, vomiting, nervousness, insomnia, headache, dizziness, lightheadedness, hair loss, and weight gain. Most side effects are dose-related and generally disappear after discontinuation of therapy. Severe OHSS occurs in approximately 0.5-2% of patients and requires immediate medical attention.
Drug interaction
Fertomid may interact with thyroid medications, corticosteroids, and other hormonal therapies. Concomitant use with gonadotropins may increase the risk of ovarian hyperstimulation. Estrogen-containing medications may interfere with Fertomid’s mechanism of action. Drugs that induce liver enzymes (such as rifampin, phenobarbital, carbamazepine) may reduce clomiphene concentrations, while drugs that inhibit CYP2D6 may increase levels. Always inform your physician of all medications, including over-the-counter products and supplements.
Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for a missed one. Contact your healthcare provider for guidance if multiple doses are missed, as this may affect treatment efficacy. Consistent dosing is important for optimal follicular development.
Overdose
Symptoms of overdose may include nausea, vomiting, vasomotor flushes, visual disturbances, and ovarian enlargement. There is no specific antidote for clomiphene citrate overdose. Treatment should be symptomatic and supportive. Hemodialysis is not expected to be effective due to high protein binding. In case of suspected overdose, seek immediate medical attention and contact a poison control center.
Storage
Store at room temperature (15-30°C or 59-86°F) in a dry place protected from light. Keep in the original container with the lid tightly closed. Do not store in bathroom cabinets where moisture may accumulate. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any unused medication after treatment completion.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment with Fertomid should only be undertaken under the supervision of a qualified healthcare professional familiar with infertility management. Individual response to therapy may vary, and not all patients will achieve successful ovulation or pregnancy. The prescribing physician should thoroughly evaluate each patient’s specific medical situation before initiating treatment.
Reviews
Clinical studies demonstrate that approximately 80% of appropriately selected anovulatory women will ovulate in response to Fertomid, with cumulative pregnancy rates of approximately 30-40% over three to six treatment cycles. The multiple pregnancy rate is approximately 8%, with most being twin gestations. Patient satisfaction surveys indicate that most women appreciate the oral administration and relatively low side effect profile compared to injectable alternatives. However, patients should maintain realistic expectations regarding treatment success and potential need for additional fertility interventions.